The active agent in the nasal spray, 2-bromopalmitate, carries a high risk of interfering with a number of processes, making ...

Cassava Sciences Inc.’s stock tumbled 85% Monday to put it on track for its biggest-ever one-day decline, after the ...

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...

Since a schizophrenia drug, the first in decades with an innovative mechanism of action, gained US regulatory approval in ...

While food and lifestyle changes can't completely reverse the effects of Alzheimer's disease, your plate could go a long way ...

To determine the diagnostic accuracy of the results of CSF tests compared to the gold standard PET imaging, the Munich researchers evaluated the data of over 400 patients with suspected Alzheimer's ...

A brain region affected very early in Alzheimer's disease may explain why some aging people are at greater risk of financial exploitation. That is the key finding of our new study, published in the ...

Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...

The earlier MCI due to AD and mild AD dementia are diagnosed and treated, the greater the opportunity for benefit.

D. Boral Capital keeps a Buy rating on Anavex Life Sciences (AVXL) with a $46 price target after Cassava Sciences’ (SAVA) Phase 3 trial for ...

TAMPA — November marks National Alzheimer’s Disease Awareness Month. According to the Alzheimer’s Association, nearly 7 ...